Admission to Trading Announcement

Summary by AI BETAClose X

Malibu Life Holdings Limited announced the admission to trading of 84,999 new ordinary shares of US$0.01 each on the London Stock Exchange's Main Market, effective 15 September 2026. These shares were issued pursuant to the vesting of conditional awards under the Malibu Life Omnibus Incentive Plan. Following this issuance, the company's total number of ordinary shares in issue will be 25,777,809, and these new shares are fully fungible with existing ordinary shares.

Disclaimer*

ADMISSION TO TRADING
Date: 15 September 2026

Company: Malibu Life Holdings Limited
LEI: 549300WXTCG65AQ7V644

Malibu Life Holdings Limited
(the "Company")

Notification of Admission to Trading of Further Securities (PRM 1.6.4R)

Further to the Company’s announcement on 11 September 2026 of the allotment and issue of 84,999 new ordinary shares of US$0.01 each in the Company pursuant to the vesting of certain conditional awards over ordinary shares of US$0.01 each in the Company on 8 June 2026 granted subject to the rules of the Malibu Life Omnibus Incentive Plan, the below information is disclosed in accordance with the PRM 1.6.4R of the Prospectus Rules: Admission to Trading on a Regulated Market sourcebook of the Financial Conduct Authority.

Details of the issuer
Name Malibu Life Holdings Limited
LEI 549300WXTCG65AQ7V644
Details of the transferable securities admitted to trading
Name, type and identification code Ordinary sharesISIN: KYG8827C1006
Regulated Market London Stock Exchange – Main Market
Number of further securities admitted 84,999 ordinary shares
Total number of securities in issue following admission 25,777,809 ordinary shares
Fungibility Fully fungible with existing ordinary shares
Admission details
Date of admission 15 September 2026
Prospectus information Prospectus: N/ASupplementary: N/ACompany’s website: https://www.malibulifeinsurance.com/resources/

Enquiries

Company Secretary +1 (345) 814-7600
Walkers Corporate Limited
Investor Contact ir@malibulifeinsurance.com
Investor relations (212) 715-6707



UK 100

Latest directors dealings